In recent generic drug developments, Par and Mylan launched versions of Novartis Pharmaceuticals Inc.'s Focalin XR.
Also, Perrigo filed an abbreviated new drug application (ANDA) for a version of Dow Pharmaceutical Sciences Inc.'s Acanya Gel, and Actavis filed an ANDA for a version of Eli Lilly’s Axiron.
Par Pharmaceutical Cos. Nov. 20 announced it has begun shipping its version of Novartis Pharmaceuticals Inc.'s Focalin XR (dexmethylphenidate hydrochloride) 15 mg and 30 mg extended-release capsules following approval by the FDA.
Focalin XR is indicated for treating attention deficit hyperactivity disorder (ADHD) in patients 6 years old and older.
Par, which is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.